Ehlers-Danlos Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 Ehlers-Danlos syndrome is a group of connective tissue disorders that are characterized by unstable, hypermobile joints, loose, “stretchy” skin, and tissue fragility. It is caused by a defect in the connective tissue. The fragile tissues, stretchy skin, and unstable joints found in Ehlers-Danlos syndrome are due to a gene mutation in collagen. Vascular Ehlers-Danlos syndrome is an autosomal dominant condition; that is, a child only has to inherit a defect in the COL3A1 gene from one parent to have the disorder. About half of people with vascular Ehlers-Danlos syndrome inherited the COL3A1 mutation from an affected parent. The other half of people with the condition have a spontaneous disease-causing mutation; that is, they are the first person in their family to have vascular Ehlers-Danlos syndrome. Each child of an affected parent has a 50 percent chance of inheriting the mutation and developing the disorder.

·       The estimated prevalence of Ehlers-Danlos syndrome is 1 in every 5,000 birth.

 

Thelansis’s “Ehlers-Danlos Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Ehlers-Danlos Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Ehlers-Danlos Syndrome across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Ehlers-Danlos Syndrome Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Ehlers-Danlos Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Ehlers-Danlos Syndrome, Ehlers-Danlos Syndrome market outlook, Ehlers-Danlos Syndrome competitive landscape, Ehlers-Danlos Syndrome market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033